Save $50 on the Ember Smart Mug 2, my favorite tech gadget
Buy the Ember Smart Mug 2 10oz for just $79.99 ($50 off)
This offer is available from Amazon. The only caveat is that the discount only applies to the Black color version. All other variants cost more. Also, keep in mind this offer is for the 10oz version.
I buy very few things, and like to keep things simple. The truth is, even at $79.99, this is pricey for a mug. I value my coffee and tea times, though, so it quickly became my favorite tech gadget. I can no longer go back to regular mugs, and feel like every penny I spent on this is totally worth it. And I actually paid $109.99 for it, so you're getting a much better deal.
The mug keeps your drink at the right temperature at all times. You can set your preferred temperature using the official app, and the mug will keep your drink at that level indefinitely. It connects to your phone via Bluetooth. The product literally only has one job, but it does it amazingly well!
You can set the temperature anywhere between 120 and 145 degrees Fahrenheit. After a bunch of testing, I found that my favorite temperature is 138 degrees. You can experiment, but the app also has some default presets you can use if you're not sure.
Yes, I know many of you will argue that there are plenty of other electric heating mugs out there that do the same for much less money. Well, there are a few things that make this one special. For starters, we already mentioned the app support. Additionally, the Ember Smart Mug 2 comes with an internal battery that can make it last for about 1.5 hours off the charging dock. Most other cheaper heating mugs only heat while docked.
I also love that the Ember Smart Mug 2 knows when you pour liquid into it and automatically starts heating the liquid within to your last set temperature. It also knows when it is empty and turns itself off. Pretty awesome, right?
The mug has an LED light you can customize, and it will give you the current status at a glance. It will let you know when it is charging, when it is heating, and when the drink has reached your desired temperature.
You won't need to worry about washing it, as it has an IPX7 rating. It's water-resistant and perfectly safe to wash. Just make sure you dry the connections in the bottom before you dock it again.
I absolutely love the Ember Smart Mug 2. I would love it even more if it cost me $79.99! Take advantage of this deal while you can.
I absolutely love my Ember Mug 2, and I would like it even more if I had paid only $74.99 for it. Catch this deal while you can. I am pretty sure it will go away relatively soon. And while only the White model is discounted this cheap, I happen to think it has a very nice, clean look!
Follow
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26 minutes ago
- Forbes
What The Worst Jobs Report In 15 Years Means For All Americans
Washington DC USA , Sep 03 2019 : Labor sign and building. getty The American job market suffered its worst hit in 15 years (with the exception of Covid); our Denier-in-Chief immediately declared the July Jobs Report 'rigged' by Erika McEntarfer, commissioner of the Bureau of Labor Statistics (BLS) to make him and other Republicans 'look bad;' and Mr. Trump proceeded to tread all over historical objectivity, bipartisan fairness, and professional excellence. President Donald Trump took one look at the report and fired McEntarfer. Trump, in essence, didn't like the message so he took an unprecedented step He shot the messenger. In his rantings and ravings, all of which began only minutes after the report was released, Trump accused McEntarfer of two things: bad reporting and political motivation. This was neither. For the record, there appears to be no other confirmed case in U.S. history of a Senate‑confirmed, cabinet-level official being dismissed specifically for delivering a report with 'bad' news. The Senate confirmed McEntarfer, a Biden pick, by a vote of 86-8, clearly bipartisan, Monthly Jobs Reports have been issued by the BLS ever since 1939, always keeping to the same methodology and protocol. One thousand twenty-/five reports – both good news and bad – have been unassailable, and there is every reason to believe that has continued. Not only were July's numbers – 73,000 jobs created – among the lowest of the last 15 years, but the previous two months were revised sharply downward by a combined 258,000 – May and June to 19K and 14K – yielding in the past three months a level lower than any three-month figure other than Covid's ransacking of the workplace of the past 15 years. These revisions are standard operating procedure, and happen every month. If I were Trump, I'd be upset, too, but not at McEntarfer. A more granular look is alarming. Of the 73,000 jobs, 55,000 came in health care – not a surprise – leaving only 18,000 for the rest of the entire economy. Trump can blame anyone he wants for that but it's still a frightening thing. It is this writer's strong suspicion that these disastrous numbers were self-inflicted and brewing under the surface since Trump's inauguration and immediate creation of DOGE with Elon Musk's chain saw-yielding symbolism. Analysts and observers everywhere – me included – were waiting for this – and it finally hit – with a second shoe certainly looming above and ready to drop. Probably more. The chickens are coming home to roost, all our career readiness and job search strategies are now in play, and the battle is joined.
Yahoo
27 minutes ago
- Yahoo
Analyst makes surprising prediction about Tesla stock despite major concerns: 'Likely to overshadow'
Despite recent legislation that has rolled back electric vehicle and other renewable energy tax incentives, one analyst believes Tesla will continue to be profitable, in accordance with his $400 per share price target and the stock's "Overweight" rating. According to Teslarati, analyst Alex Potter released an investor note, estimating that Tesla would earn $3 billion in zero-emission vehicle credits, only $500,000 less than in 2024. Potter posited that even with the One Big Beautiful Bill Act's cutting of EV incentives, such as the $7,500 federal tax credit on qualified EV purchases, the effect on the EV titan will likely be slight. "Tesla will still book around $3B in credits this year, followed by $2.3B in 2026," Potter said, according to an X post Teslarati shared from software developer Hardick Shah (AIStockSavvy), who posted a screenshot of the investor note. In early 2025, Tesla sales saw record declines in early 2025, in part due to CEO Elon Musk's polarizing involvement in U.S. politics. However, developments like Tesla's robotaxi service — which has recently been updated and expanded in Austin, Texas — as well as the company's continued efforts to perfect the Full Self-Driving program have sparked optimism for the brand. Despite ongoing efforts, concerns still remain about the safety of Tesla's supervised FSD systems and other autonomous features. "In our view, these favorable FSD-related developments are likely to overshadow any/all negative commentary arising from lower 2025/2026 estimates," Potter said, as reported by Teslarati. Though the federal tax credit on EVs is set to end by Sept. 30, increased releases of affordable EVs, as well as a growing used EV market, have made going electric feasible for more people. Plus, by switching to an EV, not only do people save money on maintenance, as there's no need for gas or oil changes, but they also contribute to healthier air quality. EVs do not emit the toxic tailpipe exhaust like gas-powered cars. It can be a win for your wallet and the Earth. If you do switch to an EV, installing solar panels can help you make the most of its benefits by keeping charging costs down and promoting your personal investment in clean energy even further. If you aren't sure where to start with solar panel installation, EnergySage provides free estimates and other resources to find which option is best for you. Would you buy an EV if there were no tax incentives for getting one? Definitely No way Depends on the sticker price Depends on the range Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
41 minutes ago
- Yahoo
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
- Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET PASADENA, Calif., August 07, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "We continue to maintain a strong balance sheet, which we believe gives us the financial resources to move multiple innovative new medicines through the clinical and regulatory process and ultimately get them to the patients who need them." Selected Recent Events Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Summary terms of the agreement include: Visirna will receive an upfront payment of $130 million from Sanofi. In addition, Visirna will be eligible to receive further milestone payments of up to $265 million upon approval of plozasiran across various indications in mainland China. Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides. Earned a $100 million milestone payment from Sarepta Therapeutics when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment from Sarepta. Completed enrollment in investigational plozasiran clinical studies SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. Dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen). Dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes. Selected Fiscal 2025 Third Quarter Financial Results ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Three Months Ended June 30, OPERATING SUMMARY 2025 2024 (Unaudited) Revenue $ 27,767 $ — Operating Expenses: Research and development 162,368 152,431 General and administrative expenses 30,949 23,710 Total operating expenses 193,317 176,141 Operating loss (165,550 ) (176,141 ) Total other (expense) income (13,539 ) 2,164 Loss before income tax expense and noncontrolling interest (179,089 ) (173,977 ) Income tax (benefit) expense (437 ) — Net loss including noncontrolling interest (178,652 ) (173,977 ) Net loss attributable to noncontrolling interest, net of tax (3,411 ) (3,184 ) Net loss attributable to Arrowhead Pharmaceuticals, Inc. $ (175,241 ) $ (170,793 ) Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.26 ) $ (1.38 ) Weighted-average shares used in calculating - Diluted 139,039 124,199 FINANCIAL POSITION SUMMARY June 30, 2025 September 30, 2024 (unaudited) Cash, cash equivalents and restricted cash $ 129,793 $ 102,685 Available-for-sale securities, at fair value 770,579 578,276 Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) 900,372 680,961 Other current and long-term assets 480,240 458,841 Total Assets $ 1,380,612 $ 1,139,802 Liability related to the sale of future royalties $ 360,254 $ 341,361 Credit Facility 240,332 393,183 Deferred revenue 22,979 — Other liabilities 237,241 214,195 Total Liabilities $ 860,806 $ 948,739 Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity 522,313 185,444 Noncontrolling Interest (2,507 ) 5,619 Total Noncontrolling Interest and Stockholders' Equity $ 519,806 $ 191,063 Total Liabilities, Noncontrolling Interest and Stockholders' Equity $ 1,380,612 $ 1,139,802 Shares Outstanding 138,144 124,376 Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of the next ARO-DM1 milestone, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@
